Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $135.8 million.

  • Dr Reddys Laboratories' Net Income towards Common Stockholders fell 1884.12% to $135.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $319.9 million, marking a year-over-year decrease of 3260.2%. This contributed to the annual value of $663.0 million for FY2025, which is 143.73% down from last year.
  • Per Dr Reddys Laboratories' latest filing, its Net Income towards Common Stockholders stood at $135.8 million for Q4 2025, which was down 1884.12% from $184.1 million recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' Net Income towards Common Stockholders ranged from a high of $184.1 million in Q1 2025 and a low of $152.0 during Q3 2022
  • For the 5-year period, Dr Reddys Laboratories' Net Income towards Common Stockholders averaged around $130.1 million, with its median value being $149.9 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 9999.98% in 2022, then skyrocketed by 11778634501.85% in 2023.
  • Dr Reddys Laboratories' Net Income towards Common Stockholders (Quarter) stood at $11.0 million in 2021, then soared by 962.09% to $116.8 million in 2022, then soared by 41.75% to $165.6 million in 2023, then increased by 1.08% to $167.4 million in 2024, then fell by 18.84% to $135.8 million in 2025.
  • Its last three reported values are $135.8 million in Q4 2025, $184.1 million for Q1 2025, and $167.4 million during Q4 2024.